ReviewProceedings. Biological sciences2017
Reversing resistance: different routes and common themes across pathogens.
Review in Proceedings. Biological sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- A plasmid-encoded detoxification system contributing to the survival ofApplied and environmental microbiology · 2026Article
- Rapid growth phenotype of carbapenem-resistant Enterobacter cloacae: growth fitness, stability, and mechanistic insights.BMC genomics · 2026Article
- Tripartite Loops Reverse Antibiotic Resistance.Molecular biology and evolution · 2025Article
- Exposure to Low Doses of Biocides Increases Resistance to Other Biocides and to Antibiotics in Strains ofBiology · 2025Article
- Epidemiology, mechanisms, and clinical impact of bacterial heteroresistance.npj antimicrobials and resistance · 2025Review
- Theoretical considerations and empirical predictions of the pharmaco- and population dynamics of heteroresistance.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Assessing the predictability of fungicide resistance evolution through in vitro selection.Journal of plant diseases and protection : scientific journal of the German Phytomedical Society (DPG) · 2024Article
- Theoretical Considerations and Empirical Predictions of the Pharmaco- and Population Dynamics of Heteroresistance.bioRxiv : the preprint server for biology · 2023Article
- Natural selection has driven the recurrent loss of an immunity gene that protectsProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model.Scientific reports · 2021Article
- Is antimicrobial resistance evolution accelerating?PLoS pathogens · 2020Review
- Genomics ofFrontiers in microbiology · 2020Article
- Quantifying the impact of treatment history on plasmid-mediated resistance evolution in human gut microbiota.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification.Nature microbiology · 2019Article
- Resistance Gene Carriage Predicts Growth of Natural and ClinicalApplied and environmental microbiology · 2019Article
- Identification of Collateral Sensitivity to Dihydroorotate Dehydrogenase Inhibitors in Plasmodium falciparum.ACS infectious diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance spreads rapidly in pathogen or pest populations exposed to biocides, such as fungicides and antibiotics, and in many cases new biocides are in short supply. How can resistance be reversed in order to prolong the effectiveness of available treatments? Some key parameters affecting reversion of resistance are well known, such as the fitness cost of resistance. However, the population biological processes that actually cause resistance to persist or decline remain poorly characterized, and consequently our ability to manage reversion of resistance is limited. Where do susceptible genotypes that replace resistant lineages come from? What is the epidemiological scale of reversion? What information do we need to predict the mechanisms or likelihood of reversion? Here, we define some of the population biological processes that can drive reversion, using examples from a wide range of taxa and biocides. These processes differ primarily in the origin of revertant genotypes, but also in their sensitivity to factors such as coselection and compensatory evolution that can alter the rate of reversion, and the likelihood that resistance will re-emerge upon re-exposure to biocides. We therefore argue that discriminating among different types of reversion allows for better prediction of where resistance is most likely to persist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.